CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$1.98 USD
+0.06 (3.13%)
Updated Apr 26, 2024 03:49 PM ET
After-Market: $1.96 -0.02 (-1.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CANF 1.98 +0.06(3.13%)
Will CANF be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CANF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CANF
Can-Fite (CANF) Up on Liver Cancer Study Update of Namodenoson
Can-Fite Biopharma Ltd (CANF) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
CANF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 27th
New Strong Buy Stocks for October 27th
Can-Fite (CANF) Up on Namodenoson Progress in Pancreatic Cancer
Other News for CANF
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Can-Fite Reports Breakthrough in Liver Cancer Treatment
Can-Fite BioPharma publishes article relating to namodenoson
Can-Fite’s Namodenoson Shows Promise for Liver Cancer